Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

AXSM

Axsome Therapeutics Inc

Apr 16 • 02:21PM ET

68.86

Dollar change +0.65
Percentage change 0.95	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VB IWM VXF VBK IWO IBB SCHA VTWO VHT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-5.20	Insider Own	18.14%	Shs Outstand	47.35M	Perf Week	-5.21%
Market Cap	3.26B	Forward P/E	94.42	EPS next Y	0.73	Insider Trans	-0.66%	Shs Float	38.78M	Perf Month	-8.85%
Income	-239.24M	PEG	-	EPS next Q	-1.18	Inst Own	80.85%	Short Float	19.73%	Perf Quarter	-18.95%
Sales	270.60M	P/S	12.05	EPS this Y	29.88%	Inst Trans	16.51%	Short Ratio	10.49	Perf Half Y	3.59%
Book/sh	4.03	P/B	17.07	EPS next Y	119.73%	ROA	-52.02%	Short Interest	7.65M	Perf Year	0.52%
Cash/sh	8.15	P/C	8.45	EPS next 5Y	-	ROE	-159.21%	52W Range	55.02 - 98.40	Perf YTD	-13.49%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-35.53%	ROI	-63.61%	52W High	-30.03%	Beta	1.14
Dividend TTM	-	Quick Ratio	3.52	Sales past 5Y	88.16%	Gross Margin	87.43%	52W Low	25.15%	ATR (14)	3.21
Dividend Ex-Date	-	Current Ratio	3.63	EPS Y/Y TTM	-13.57%	Oper. Margin	-67.59%	RSI (14)	36.24	Volatility	3.75% 4.51%
Employees	545	Debt/Eq	0.98	Sales Y/Y TTM	440.80%	Profit Margin	-88.41%	Recom	1.31	Target Price	123.00
Option/Short	Yes / Yes	LT Debt/Eq	0.97	EPS Q/Q	-47.88%	Payout	-	Rel Volume	0.54	Prev Close	68.21
Sales Surprise	3.31%	EPS Surprise	-77.57%	Sales Q/Q	193.50%	Earnings	May 06 BMO	Avg Volume	729.16K	Price	68.86
SMA20	-8.02%	SMA50	-13.85%	SMA200	-8.08%	Trades		Volume	297,272	Change	0.95%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-19-24	Initiated	Robert W. Baird	Outperform	$108
Feb-06-24	Initiated	UBS	Buy	$111
Jan-25-24	Initiated	RBC Capital Mkts	Outperform	$126
Dec-13-23	Initiated	Citigroup	Buy	$125
Aug-08-23	Upgrade	BofA Securities	Underperform → Neutral	$59 → $81
Jan-05-23	Initiated	Piper Sandler	Neutral	$75
Nov-01-22	Initiated	Loop Capital	Buy	$95
Sep-07-22	Resumed	Mizuho	Buy	$49 → $76
Aug-10-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$105 → $34
Jun-10-21	Initiated	Berenberg	Buy	$112
Jan-08-21	Initiated	Jefferies	Buy	$129
Dec-16-20	Initiated	Mizuho	Buy	$120
Sep-29-20	Initiated	BofA Securities	Underperform	$66
Sep-10-20	Initiated	Morgan Stanley	Overweight	$102
Apr-28-20	Reiterated	H.C. Wainwright	Buy	$200 → $210
Apr-14-20	Initiated	Cowen	Outperform	$95
Dec-30-19	Reiterated	H.C. Wainwright	Buy	$170 → $200
Dec-17-19	Reiterated	H.C. Wainwright	Buy	$30 → $170
Dec-16-19	Reiterated	Guggenheim	Buy	$65 → $158
Oct-16-19	Initiated	Guggenheim	Buy	$48

Show Previous Ratings

Apr-15-24 07:00AM	Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting (GlobeNewswire)
Apr-10-24 07:00AM	Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6 (GlobeNewswire)
Apr-02-24 10:24AM	Axsome (AXSM) Begins Solriamfetol Binge Eating Phase III Study (Zacks)
12:17AM	Insider Sell: COO Mark Jacobson Sells 24,662 Shares of Axsome Therapeutics Inc (AXSM) (GuruFocus.com)
Apr-01-24 07:00AM	Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder (GlobeNewswire)
07:44AM	Loading…
Mar-27-24 07:44AM	3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List (InvestorPlace)
Mar-26-24 11:24AM	Axsome's (AXSM) Narcolepsy Drug Study Meets Primary Goal (Zacks)
06:24AM	30 Countries with the Lowest Depression Rates (Insider Monkey)
04:56AM	20 Cloudiest Cities in the U.S., Ranked (Insider Monkey)
Mar-25-24 07:00AM	Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients (GlobeNewswire)
06:30AM	Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy (GlobeNewswire)
Mar-23-24 06:45AM	Buying These Dirt-Cheap Stocks Could Be a Brilliant Move (Motley Fool)
Mar-22-24 10:00AM	Axsome Triumphs Over Major Depressive Disorder With Auvelity (GuruFocus.com)
Mar-21-24 11:30AM	Why Is Axsome (AXSM) Down 4% Since Last Earnings Report? (Zacks)
Mar-20-24 12:12PM	Axsome (AXSM) Begins Dosing in Depression Study on Sunosi (Zacks)
07:00AM	Loading…
Mar-19-24 07:00AM	Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder (GlobeNewswire) +5.97%
Mar-13-24 03:32PM	11 Oversold NASDAQ Stocks To Buy Right Now (Insider Monkey)
Mar-05-24 07:00AM	Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference (GlobeNewswire)
Feb-27-24 07:00AM	Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference (GlobeNewswire)
Feb-26-24 03:04PM	3 Under-the-Radar Biotech Stocks With Upcoming Catalysts in 2024 (InvestorPlace)
08:50AM	3 Biotech Stocks to Buy and Hold for the Next 10 Years (Motley Fool)
Feb-21-24 10:39AM	Axsome (AXSM) Stock Falls Despite Q4 Earnings & Revenue Beat (Zacks)
09:23AM	Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-20-24 10:39PM	Q4 2023 Axsome Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -12.57%
08:15AM	Axsome Therapeutics (AXSM) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:31AM	Axsome Therapeutics Inc (AXSM) Reports Robust Revenue Growth in Q4 and Full Year 2023 (GuruFocus.com)
07:00AM	Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-13-24 10:00AM	Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks) -5.51%
Feb-08-24 07:45AM	2 Stocks That Could Double Your Money in 5 Years (Motley Fool)
Jan-23-24 11:01AM	Axsome Therapeutics Stock Showing Leadership, Earns 91 RS Rating (Investor's Business Daily)
07:00AM	Loading…
07:00AM	Axsome Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20 (GlobeNewswire)
Jan-05-24 10:21AM	Axsome (AXSM) Stock Rises on Stellar Q4 Preliminary Results (Zacks)
Jan-04-24 07:00AM	Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones (GlobeNewswire) +7.75%
Jan-03-24 05:20AM	3 Stocks That Have Turned $50,000 Into More Than $500,000 in Just 5 Years (Motley Fool)
Jan-02-24 08:45AM	2 Biotech Stocks You Can Buy and Hold for the Next Decade (Motley Fool)
Jan-01-24 06:50AM	Prediction: These 3 Stocks Will Soar in 2024 (Motley Fool)
Dec-11-23 07:00AM	Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting (GlobeNewswire)
Dec-10-23 06:56AM	3 Unstoppable Stocks to Buy Right Now (Motley Fool)
Dec-07-23 07:00AM	Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event with Expert Thought Leaders Today (GlobeNewswire)
Nov-28-23 06:51PM	Axsome Therapeutics, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; December 7, 2023 deadline. (GlobeNewswire)
Nov-27-23 09:50AM	11 Best Upside Stocks To Buy Right Now (Insider Monkey) +5.93%
Nov-22-23 07:00AM	Axsome Therapeutics to Host Solriamfetol Virtual Investor Event on December 7 (GlobeNewswire)
05:30AM	3 Biotech Stocks That Could Be Millionaire Makers (Motley Fool)
Nov-21-23 07:00AM	Axsome Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference (GlobeNewswire)
Nov-11-23 06:50AM	3 Growth Stocks to Buy Right Now Without Any Hesitation (Motley Fool)
Nov-09-23 10:23AM	3 Healthcare Stocks That Have More Than Doubled in Value Since the Fed Started Raising Interest Rates (Motley Fool)
Nov-07-23 11:02AM	Axsome (AXSM) Q3 Loss Widens, Revenues Surpass Estimates (Zacks)
08:33AM	Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q3 2023 Earnings Call Transcript (Insider Monkey)
02:23AM	Q3 2023 Axsome Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-06-23 08:09AM	Axsome Therapeutics Inc (AXSM) Reports 244% YoY Growth in 3Q 2023 Product Revenue (GuruFocus.com)
07:00AM	Axsome Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-02-23 07:00AM	Axsome Therapeutics and the Global Alzheimer's Disease Community Come Together in Raising Support for the Millions Affected by This Illness During Alzheimer's Disease Awareness Month 2023 (GlobeNewswire)
Oct-31-23 07:00AM	Axsome Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Oct-27-23 05:00AM	Got $2,000? Here Are 2 Beaten-Down Growth Stocks to Buy Right Now (Motley Fool)
Oct-25-23 08:45AM	2 Biotech Stocks You Can Buy and Hold for the Next Decade (Motley Fool)
Oct-24-23 07:00AM	Axsome Therapeutics Presents Results of the ACCORD trial of AXS-05 in Alzheimer's Disease Agitation at the Clinical Trials on Alzheimer's Disease (CTAD) 2023 Conference (GlobeNewswire)
Oct-23-23 05:30AM	3 No-Brainer Stocks to Buy Right Now for Less than $100 (Motley Fool)
Oct-11-23 07:00AM	Axsome Therapeutics Appoints Dr. Sue Mahony to its Board of Directors (GlobeNewswire)
Oct-10-23 07:00AM	Axsome Therapeutics to Report Third Quarter 2023 Financial Results on November 6 (GlobeNewswire)
Oct-03-23 05:30AM	2 Top Biotech Stocks to Buy in October (Motley Fool)
Oct-02-23 07:00AM	Axsome Therapeutics Joins the National Alliance on Mental Illness and Others Advocating for the Importance of Mental Health on Mental Illness Awareness Week (GlobeNewswire)
Sep-21-23 07:00AM	Axsome Therapeutics Joins the Global Narcolepsy Community in Raising Awareness on World Narcolepsy Day (GlobeNewswire)
Sep-15-23 10:23AM	2 Top Biotech Stocks Defying the Bear Market (Motley Fool)
Sep-12-23 06:00AM	2 No-Brainer Biotech Stocks to Buy Right Now (Motley Fool)
Sep-07-23 07:03AM	Axsome Therapeutics Highlights Commitment to Innovating Treatments for Mental Health Conditions with Presentations at Psych Congress 2023 (GlobeNewswire)
Sep-05-23 07:00AM	Axsome Therapeutics to Present at Three Upcoming Investor Conferences (GlobeNewswire)
Aug-30-23 08:00AM	The Top Healthcare Stocks to Buy With $100 (Motley Fool)
Aug-24-23 10:07AM	These 3 Stocks Have Underperformed the Market This Year. Is Now the Time to Buy? (Motley Fool)
Aug-19-23 05:52AM	Got $200? 3 Growth Stocks to Buy That Could Double Your Money (Motley Fool)
Aug-10-23 05:50AM	3 Explosive Stocks to Buy Right Now (Motley Fool)
Aug-09-23 08:37AM	Axsome Therapeutics Second Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.)
Aug-08-23 12:21PM	Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q2 2023 Earnings Call Transcript (Insider Monkey)
10:02AM	DraftKings upgraded, Home Depot downgraded: Wall Street's top analyst calls (The Fly)
09:11AM	Axsome (AXSM) Q2 Earnings Beat, Stock Dips on Pipeline Updates (Zacks)
03:42AM	Q2 2023 Axsome Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-07-23 07:00AM	Axsome Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Aug-05-23 06:55AM	3 Fantastic Growth Stocks to Buy in August (Motley Fool)
Aug-03-23 09:45AM	Got $5,000? These 2 Stocks Could Be Bargain Buys for 2023 and Beyond (Motley Fool)
Aug-02-23 10:23AM	Axsome Therapeutics, Inc. (NASDAQ:AXSM) Is Expected To Breakeven In The Near Future (Simply Wall St.) -5.26%
Jul-20-23 08:08AM	The 3 Most Undervalued Biotech Stocks to Buy Now: July 2023 (InvestorPlace)
Jul-13-23 05:50AM	Got $500? 3 Growth Stocks to Buy That Could Double Your Money (Motley Fool)
Jul-12-23 07:00AM	Axsome Therapeutics to Report Second Quarter 2023 Financial Results on August 7 (GlobeNewswire)
Jul-11-23 10:00AM	Best Momentum Stocks to Buy for July 11th (Zacks)
Jul-07-23 07:00AM	Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults (GlobeNewswire)
Jul-01-23 05:45AM	5 Top Stocks for July (Motley Fool)
Jun-30-23 04:02PM	Axsome Therapeutics Announces Closing of Public Offering of $225 Million of Shares of Common Stock (GlobeNewswire)
Jun-28-23 03:59PM	Why Shares of Axsome Therapeutics Fell Wednesday (Motley Fool) -10.06%
09:28AM	Axsome Therapeutics Announces Pricing of Public Offering of $225 Million of Shares of Common Stock (GlobeNewswire)
09:25AM	As the Bull Roars, Shareholders Hate How These 2 Companies Are Selling Their Stock (Motley Fool)
07:45AM	2 Under-the-Radar Biotech Stocks to Buy in 2023 (Motley Fool)
05:30AM	The Best Stocks to Invest $20,000 in Right Now (Motley Fool)
Jun-27-23 08:24PM	Axsome Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Jun-25-23 06:07AM	3 Monster Stocks in the Making to Buy Right Now (Motley Fool)
Jun-22-23 06:40AM	3 Biotech Stocks to Buy as Companies Ink Major Deals (InvestorPlace)
Jun-20-23 08:23AM	Where Will Axsome Therapeutics Be in 3 Years? (Motley Fool)
Jun-17-23 05:17AM	Does an $11.5 Billion Opportunity Make This Growth Stock a Buy Now? (Motley Fool)
Jun-16-23 02:00PM	This Stock Crushed the Market Last Year. Here's Why It Could Do That Again. (Motley Fool)
Jun-15-23 02:00PM	Is Axsome Therapeutics Stock a Screaming Buy? (Motley Fool)
Jun-14-23 04:01PM	Axsome Therapeutics Expects Up To $11.5 Billion In Peak Sales, Wallops Analysts' Forecasts (Investor's Business Daily) +8.05%
Jun-10-23 06:14AM	3 No-Brainer Stocks to Buy in June (Motley Fool)

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview contain AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Jacobson Mark L.	Chief Operating Officer	Apr 01 '24	Option Exercise	1.30	24,662	32,061	24,662	Apr 01 06:46 PM
Jacobson Mark L.	Chief Operating Officer	Apr 01 '24	Sale	77.24	24,662	1,904,942	0	Apr 01 06:46 PM
JEFFS ROGER	Director	Mar 15 '24	Option Exercise	29.91	2,347	70,199	123,103	Mar 15 08:05 PM
JEFFS ROGER	Director	Mar 15 '24	Sale	71.61	2,347	168,062	120,756	Mar 15 08:05 PM
JEFFS ROGER	Director	Mar 14 '24	Option Exercise	24.01	29,976	719,787	137,732	Mar 15 08:05 PM
JEFFS ROGER	Director	Mar 14 '24	Sale	69.70	29,976	2,089,387	120,756	Mar 15 08:05 PM
Coleman Mark	Director	Sep 15 '23	Option Exercise	3.67	11,016	40,429	36,113	Sep 15 06:30 PM
Coleman Mark	Director	Sep 15 '23	Sale	75.18	18,572	1,396,189	403,856	Sep 15 06:30 PM
Coleman Mark	Director	Sep 15 '23	Sale	75.19	11,016	828,241	25,097	Sep 15 06:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AXSM

Axsome Therapeutics Inc

Upgrade your FINVIZ experience